Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma

被引:22
作者
Byrne, JL
Carter, GI
Bienz, N
Haynes, AP
Russell, NH
机构
[1] City Hosp, Dept Haematol, Nottingham NG5 1PB, England
[2] Univ Nottingham, Nottingham NG7 2RD, England
关键词
allogeneic transplantation; interferon; myeloma;
D O I
10.1038/sj.bmt.1701403
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure, We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report five of 13 evaluable patients undergoing allogeneic sibling BM or PBSC transplantation for MM between 1990 and 1997 who met the criteria for adjuvant alpha-IFN therapy. A starting dose of 3 MU x 3/week was commenced at median time of day +126 (range day +112-224) posttransplant and was well-tolerated. In contrast to other reports me observed no increased toxicity in terms of GVHD compared to those patients not receiving alpha-IFN therapy and only one patient treated with alpha-IFN has developed chronic GVHD. Durable CRs were achieved in two patients within 8 weeks of starting therapy whilst two other patients required a longer course of alpha-IFN to achieve CR (36 weeks and 30 weeks, respectively). One patient whose paraprotein was rapidly rising at the time of alpha-IFN therapy clinically relapsed despite 6 months of treatment. None of the patients who achieved CR following alpha-IFN therapy have relapsed and we conclude that alpha-IFN is a safe and effective adjuvant treatment for some patients in the achievement of CR following allogeneic transplantation for myeloma.
引用
收藏
页码:639 / 643
页数:5
相关论文
共 17 条
[1]  
AVVISATI G, 1995, STEM CELLS, V13, P106
[2]   Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome [J].
Bensinger, WI ;
Buckner, CD ;
Anasetti, C ;
Clift, R ;
Storb, R ;
Barnett, T ;
Chauncey, T ;
Shulman, H ;
Appelbaum, FR .
BLOOD, 1996, 88 (07) :2787-2793
[3]   Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect [J].
Bertz, H ;
Burger, JA ;
Kunzmann, R ;
Mertelsmann, R ;
Finke, J .
LEUKEMIA, 1997, 11 (02) :281-283
[4]  
BIRD JM, 1993, BONE MARROW TRANSPL, V12, P651
[5]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[6]   ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BELANGER, C ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRANENA, A ;
GORE, M ;
GRATWOHL, A ;
LOWENBERG, B ;
NIKOSKELAINEN, J ;
REIFFERS, JJ ;
SAMSON, D ;
VERDONCK, L ;
VOLIN, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (18) :1267-1273
[7]   PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BLADE, J ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRATWOHL, A ;
HAGENBEEK, A ;
JACOBS, P ;
DELAURENZI, A ;
VANLINT, M ;
MICHALLET, M ;
NIKOSKELAINEN, J ;
REIFFERS, J ;
SAMSON, D ;
VERDONCK, L ;
DEWITTE, T ;
VOLIN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1312-1322
[8]   Allogeneic bone marrow transplantation in multiple myeloma [J].
Gahrton, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (02) :251-254
[9]  
Grander D, 1997, EUR J HAEMATOL, V59, P129
[10]  
GRESSLER VH, 1988, BLOOD, V72, P1048